Two pharmaceutical companies, Viking Therapeutics (VKTX) and Summit Therapeutics (SMMT), are expected to see significant stock price increases in 2025, according to Wall Street analysts. Viking Therapeutics’ experimental weight loss treatment, VK2735, has shown promising results in clinical trials, while Summit Therapeutics’ licensed cancer therapy, ivonescimab, has outperformed Merck’s Keytruda in studies.
Viking Therapeutics’ stock has soared 157% since the end of 2023, driven by mid-stage clinical trial results that suggest VK2735 can become a leading weight management drug. The company’s candidate has shown efficacy in reducing weight and improving metabolic health, comparable to established treatments like tirzepatide from Eli Lilly.
Summit Therapeutics’ ivonescimab has also generated significant interest, with the FDA approving its use for second-line lung cancer patients in China. Analysts expect the therapy to perform well in the US market, given its impressive results in China-based trials.
However, both companies face high risks, including the need to complete phase 3 clinical trials and intense competition in their respective markets. Investors should exercise caution before investing in these stocks.
Analysts have set price targets of $125 for Viking Therapeutics and $30 for Summit Therapeutics, suggesting potential gains of 166% and 68%, respectively. While these projections are promising, investors should be aware that past performance is not a guarantee of future success.
As with any investment, it’s essential to weigh the risks and rewards before making a decision. For those looking for growth opportunities in the pharmaceutical sector, Viking Therapeutics and Summit Therapeutics may be worth considering.
Source: https://finance.yahoo.com/news/2-soaring-stocks-could-climb-123700048.html